Provided by Tiger Trade Technology Pte. Ltd.

Biofrontera Inc

0.9250
+0.00620.67%
Volume:9K
Turnover:8.27K
Market Cap:13.74M
PE:-1.70
High:0.9250
Open:0.9250
Low:0.9200
Close:0.9188
52wk High:1.66
52wk Low:0.5547
Shares:14.85M
Float Shares:10.55M
Volume Ratio:1.28
T/O Rate:0.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5426
EPS(LYR):-1.0358
ROE:-988.35%
ROA:-17.45%
PB:2.31
PE(LYR):-0.89

Loading ...

Biofrontera submits sNDA to FDA to expand Ameluz indication

TIPRANKS
·
Yesterday

Biofrontera Submits FDA sNDA Seeking Ameluz Label Expansion for Full-Body Actinic Keratoses

Reuters
·
Yesterday

Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light Pdt to Actinic Keratoses on the Full Body

THOMSON REUTERS
·
Yesterday

Biofrontera Sets Date for Release of 2026 Half-Year Results

TIPRANKS
·
Sep 30

Biofrontera Gains FDA Approval for Ameluz Skin Cancer Use

TIPRANKS
·
Sep 14

Biofrontera announces FDA approval of Ameluz supplemental new drug application

TIPRANKS
·
Sep 14

Biofrontera Announces FDA Approval of Ameluz® Red Light Pdt for the Treatment of Superficial Basal Cell Carcinoma

THOMSON REUTERS
·
Sep 14

Biofrontera - to Launch Sbcc Indication Late Q4 2026 Through Q1 2027

THOMSON REUTERS
·
Sep 14

Biofrontera Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Biofrontera Q2 Revenue Rises on Higher Volume, Pricing

Reuters
·
Aug 13

Biofrontera Q2 EPS $(0.05) Misses $(0.04) Estimate, Sales $12.003M Beat $10.500M Estimate

Benzinga Earnings
·
Aug 13

Biofrontera Q2 Revenue USD 12 Million

Reuters
·
Aug 13

Biofrontera Q2 Adjusted Ebitda USD -200 Thousand

THOMSON REUTERS
·
Aug 13

Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth

GlobeNewswire
·
Aug 13

Biofrontera Inc Expected to Post a Loss of 10 Cents a Share - Earnings Preview

Reuters
·
Aug 11

Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026

GlobeNewswire
·
Aug 06

Biofrontera Plans Move from Prime Standard to Frankfurt’s Scale Segment

TIPRANKS
·
Jul 28

Biofrontera’s Acne PDT Trial Completion: What Investors Should Watch Next

TIPRANKS
·
Jul 09

Biofrontera’s Phase III Actinic Keratosis Study Nears Data Payoff for Investors

TIPRANKS
·
Jul 08

Biofrontera Shareholders Approve Director Elections and Equity Plan

TIPRANKS
·
Jun 18